For a full list of publications, see Laura Attardi's PubMed citation


He, B., Stoffel, L., He, C. J., Cho, K., Li, A. M., Jiang, H., Flowers, B. M., Nguyen, K. T., Wang, K. W., Zhao, A. Y., Zhou, M. N., Ferreira, S., Attardi, L. D., and J. Ye. (2024). Epigenetic priming targets tumor heterogeneity to shift transcriptomic phenotype of pancreatic ductal adenocarcinoma towards a Vitamin D susceptible state. Cell death & disease15(1), 89. PMCID: PMC10810848

Attardi, L. D. and A.M. Boutelle. (2024). Targeting p53 gain-of-function activity in cancer therapy: a cautionary tale. Cell death and differentiation, 31(2):133-135. PMCID: PMC10850540.


Kaiser, A.M., Gatto, A., Hanson, K.J., Zhao, R.L., Raj, N., Ozawa, M.G., Seoane, J.A., Bieging-Rolett, K.T., Wang, M., Li, I., Trope, W.L., Liou, D.Z., Shrager, J.B., Plevritis, S.K., Newman, A.M., Van Rechem, C., and L.D. Attardi. (2023) p53 governs an alveolar type 1 differentiation program in lung cancer suppression. Nature. Jul 19. doi: 10.1038/s41586-023-06253-8. Online ahead of print . PMID: 37468633.

Mello, S.S., Flowers, B.M., Mazur, P.K., Lee, J., Muller, F., Denny, S.K., Ferreira, S., Hanson, K.J., Kim, S., Greenleaf, W., Wood, L.D., and Laura D. Attardi. (2023) Multifaceted Role for p53 in Pancreatic Cancer Suppression. PNAS. 120(10)e2211937120 PMID: 36848578


Raj, N., Wang, M., Seoane, J.A., Zhao, R.L., Kaiser, A.M., Moonie, N.A., Demeter, J., Boutelle, A.M., Kerr, C.H.,  Mulligan, A.S., Moffatt, C., Zeng, S.X., Lu, H., Barna, M., Curtis, C., Chang, H.Y., Jackson, P.K. and L.D. Attardi. (2022) The Mettl3 epitranscriptomic writer amplifies p53 stress responses. Mol Cell. 82(13):2370-2384.e10. PMID: 35512709.

Kuo, H.C., Luo, L., Ma, Y., Williams, N.T., da Silva Campos, L., Attardi, L.D., Lee, C.L., and D.G. Kirsch. (2022) The p53 transactivation domain 1-dependent response to acute DNA damage in endothelial cells protects against radiation-induced cardiac injury, Radiat Resonline ahead of print, May 5. PMID: 35512345


Wang, M. and L.D. Attardi. (2022) A Balancing Act: p53 Activity from Tumor Suppression to Pathology and Therapeutic Implications. Annu Rev Pathol. 17:205-226. PMID: 34699262.

Tiu, G.C., Kerr, C.H., Forester, C.M., Krishnarao, P.S., Rosenblatt, H.D., Raj, N., Lantz, T.C., Zhulyn, O., Bowen, M.E., Shokat, L., Attardi, L.D., Ruggero, D., and M. Barna. (2021) A p53-dependent translational program directs tissue-selective phenotypes in a model of ribosomopathies. Dev Cell. 56(14):2089-2102.e.11.

Moon, E.J., Mello, S.S., Li, C.G., Chi, J.T., Thakkar, K., Kirkland, J.G., LaGory, E.L., Lee, I.J., Diep, A.N., Miao, Y.,  Rafat, M., Vilalta, M., Castellini, L., Krieg, A.J., Graves, E.E., Attardi, L.D., and A.J. Giaccia. (2021) The HIF target MAFF promotes tumor invasion and metastasis through IL11 and STAT3 signaling. Nat Commun. 12(1):4308.

Bowen, M., Mulligan, A., Sorayya, A. and L.D. Attardi. (2021) Puma- and Capsase9-mediated apoptosis is dispensable for p53-driven neural crest-based developmental defects. Cell Death & Differentiation. 28(7):2083-2094. PMCID: PMC8257737.

Bieging-Rolett, K.T. and L.D. Attardi. (2021) Zmat3 splices together p53-dependent tumor suppression. Mol Cell Oncol. 8(3):1898523. PMCID: PMC8128213.

Simon, D.J., Belsky, D.M., Bowen, M.E., Ohn, C.Y.J., O’Rourke, M.K., Shen, R., Kim, G., Pitts, J., Attardi, L.D. and M. Tessier-Lavigne. (2021) An anterograde pathway for sensory axon degeneration gated by a cytoplasmic action of the transcriptional regulator P53. Dev Cell. 56(7):976-984. PMCID: PMC8034543.

Flowers, B.M., Xu, H., Mulligan, A.S., Hanson, K.J., Seoane, J.A., Vogel, H., Curtis, C., Wood, L.D., and L.D. Attardi. (2021) Cell-of-origin influences pancreatic cancer subtype. Cancer Discov. 11(3):660-677.

Boutelle, A.M. and L.D. Attardi. (2021) p53 and tumor suppression: it takes a network. Trends Cell Biol. S0962-8924(21)00001-5.

Maor-Nof, M., Shipony, Z., Lopez-Gonzalez, R., Nakayama, L., Zhang, Y., Couthouis, J., Blum, J.A., Castruita, P.A., Linares, G.R., Ruan, K., Ramaswami, G., Simon, D.J., Nof, A., Santana, M., Han, K., Sinnott-Armstrong, N., Bassik, M.C., Geschwind, D.H., Tessier-Lavigne, M., Attardi, L.D., Lloyd, T.E., Ichida, J.K., Gao, F., Greenleaf, W.J., Yokoyama, J.S., Petrucelli, L., and A.D. Gitler. (2021) p53 as a central regulator driving neurodegeneration caused by C9orf72 poly(PR). Cell. 184(3):689-708.e20.

Valente, L.J. and L.D. Attardi. (2021) p53 orchestrates a complex symphony of cellular processes during oncosuppression. Mol Cell Oncol. 8(1):1852066.

Fortuno, C., Lee, K., Olivier, M., Pesaran, T., Mai, P.L., de Andrade, K., Attardi, L.D., Crowley, S., Evans, D.G., Feng, B., Foreman, A.K.M., Frone, M.N., Huether, R., James, P.A., McGoldrick, K., Mester, J., Seifert, B.A., Slavin, T.P., Witkowski, L., Zhang, L., Plon, S.E., Spurdle, A.B., and S.A. Savage. (2021) Specifications of the ACMG/AMP variant interpretation guidelines for TP53 germline variants. Hum Mutat. 42(3):223-236.


Bieging-Rolett, K.T., Kaiser, A., Morgens, D.W., Boutelle, A.M., Seoane, J.A., Van Nostrand, E.L., Zhu, C., Houlihan, S.L., Mello, S.S., Yee, B.A., McClendon, J., Pierce, S.E., Winters, I.P., Wang, M., Connolly, A.J., Lowe, S.W., Curtis, C., Yeo, G.W., Winslow, M.M., Bassik, M.C., and L.D. Attardi. (2020) Zmat3 is a key splicing regulator in the p53 tumor suppression program. Mol Cell. 80(3):452-469.e9.

Holmes, B.J., von Eyben, R., Attardi, L.D., Kong, C.S., Le, Q.T., C.A.O. Nathan. (2020) A Pilot Study of Loss of the p53/p63 Target Gene PERP at the Surgical Margin as a Potential Predictor of Local Relapse in Head and Neck Squamous Cell Carcinoma, Head Neck. 42(11):3188-3196.

Valente, L.J., Tarangelo, A., Li, A.M., Naciri, M., Raj, N., Boutelle, A.M., Li, Y., Mello, S.S., Bieging-Rolett, K., DeBerardinis, R.J., Ye, J., Dixon, S.J., and L.D. Attardi. (2020) p53 Deficiency Triggers Dysregulation of Divers Cellular Processes in Physiological Oxygen, J Cell Biol. 219(11):e201908212.

Jacobs, S.B.R., Van Nostrand, J.L., Bowen, M.E., Baker, J.C., and L.D. Attardi. (2020) Siva Plays a Critical Role in Mouse Embryonic Development, Cell Death Diff. 27(1):297-309.


Gomez-Ospina, N., Scharenberg, S.G., Mostrel, N., Bak, R.O., Mantri, S., Quadros, R.M., Gurumurthy, C.B., Lee, C., Bao, G., Suarez, C.J., Khan, S., Sawamoto, K., Tomatsu, S., Raj, N., Attardi, L.D., Aurelian, L., and M.H. Porteus. (2019) Human genome-edited hematopoietic stem cells phenotypically correct Mucopolysaccharidosis type I. Nat Commun. 10(1):4045.  

Nguyen, T.A., Bieging-Rolett, K.T., Putoczki, T.L., Wicks, I.P., Attardi, L.D., and K.C. Pang. (2019) SIDT2 RNA transporter promotes lung and gastrointestinal tumor development. iScience. 20:14-24.  

Bowen, M.E., McClendon, J., Long, H.K., Sorayya, A., Van Nostrand, J.L., Wysocka, J., and L.D. Attardi. (2019) The Spatiotemporal Pattern and Intensity of p53 Activation During Embryogenesis Dictates Phenotypic Diversity in p53-Driven Developmental Syndromes. Dev Cell. 50(2):212-228.

Bowen M.E., Attardi L.D. (2019) The role of p53 in developmental syndromes. J Mol Cell Biol. 11(3):200-211.

Duchatelet S, Boyden LM, Ishida-Yamamoto A, Zhou J, Guibbal L, Hu R, Lim YH, Bole-Feysot C, Nitschké P, Santos-Simarro F, de Lucas R, Milstone LM, Gildenstern V, Helfrich YR, Attardi LD, Lifton RP, Choate KA, Hovnanian A. (2019) Mutations in PERP Cause Dominant and Recessive Keratoderma. J Invest Dermatol. 139(2):380-390.


Durruthy-Durruthy R, Sperry ED, Bowen ME, Attardi LD, Heller S, Martin DM. (2018) Single Cell Transcriptomics Reveal Abnormalities in Neurosensory Patterning of the Chd7 Mutant Mouse Ear. Front Genet9:473.

Mello, S.S. and L.D. Attardi (2018) Neat-en-ing up our understanding of p53 pathways in tumor suppression. Cell Cycle. 31: 1-9.

Mello, S.S. and L.D. Attardi. (2018) Deciphering p53 signaling in tumor suppression. Curr Opin. Cell Biol. 51: 65-72.

Calo, E., Gu, B., Bowen, M.E., Zalc, A., Bauer, M.R., Flynn, R.A., Chang, H.Y., Swigut, T., Attardi, L.D., and J. Wysocka. (2018) Tissue-selective effects of nucleolar stress and rDNA damage in developmental disorders. Nature. 554(7690): 112-117.

Kaiser, A.M. and L.D. Attardi. (2018) Deconstructing networks of p53-mediated tumor suppression in vivo. Cell Death Differ25(1): 93-103.

Tarangelo, A., Magtanong, L., Bieging-Rolett, K.T., Li, Y., Ye, J., Attardi, L.D., and S.J. Dixon. (2018) P53 suppresses metabolic stress-induced ferroptosis in cancer cells. Cell Reports. 22(3): 569-575.


Mello, S.S., Valente, L.J., Raj, N., Seoane. J.A., Flowers, B.M., McClendon, J., Bieging-Rolett, K.T., Lee, J., Ivanochko, D., Kozak, M.M., Chang, D.T., Longacre, T.A., Koong, A.C., Arrowsmith, C.H., Kim, S.K., Hannes Vogel, H., Wood. L.D., Hruban, R.H., Curtis, C., and L.D. Attardi. (2017) A p53 super-tumor suppressor reveals a tumor suppressive p53-Ptpn14-Yap axis in pancreatic cancer. Cancer Cell. 32(4): 460-473.

Mello S.S., Sinow, C., Raj, N., Mazur, P.K., Bieging-Rolett, K., Broz, D.K., Imam, J.F.C., Vogel, H., Wood, L.D., Sage, J., Hirose, T., Nakagawa. S, Rinn, J., and L.D. Attardi.(2017) Neat1 is a p53-inducible lincRNA essential for transformation suppression. Genes Dev. 31(11): 1095-1108.  

Filipescu, D., Naughtin, M., Podsypanina, K., Lejour, V., Wilson, L., Gurard-Levin, Z.A., Orsi, G.A., Simeonova, I., Toufektchan, E., Attardi, L.D., Toledo, F., and G. Almouzni. (2017) Essential role for centromeric factors following p53 loss and oncogenic transformation. Genes Dev. 31(5): 463-480.  

Van Nostrand J.L., Bowen, M.E., Vogel, H., Barna, M., and L.D. Attardi. (2017) The p53 family members have distinct roles during mammalian embryonic development. Cell Death Differ. 24(4): 575-579.


Raj, N. and L.D. Attardi. (2016) "The transactivation domains of the p53 protein" in The p53 Protein: From Cell Regulation to Cancer. Levine, A.J. and Lozano, G. (eds.), CSH Perspectives in Medicine, pp. 51-68. 

Schmitt, A.M., Garcia, J.T., Hung, T., Flynn, R.A., Shen, Y., Qu, K., Payumo, A.Y., Peres-da-Silva, A., Broz, D.K., Baum, R., Guo, S., Chen, J.K., Attardi, L.D., and H.Y. Chang. (2016) An inducible long noncoding RNA amplifies DNA damage signaling. (2016) Nat. Genet. 48(11): 1370-1376.  

Jackson, P.K. and L.D. Attardi. (2016) p73 and FoxJ1: programming multiciliated epithelia. Trends Cell Biol. 26(4): 239-240. 

Khan, I.A., Yoo, B.H., Masson, O., Attardi, L.D. and K.V. Rosen (2016) ErbB2-dependent downregulation of a pro-apoptotic protein perp is required for oncogenic transformation of breast epithelial cells. Oncogene. (44): 5759-5769. 

Klionsky, D.J. et al. (2016) Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 12(1): 1-222. 

Bieging-Rolett, K.T., Johnson, T.M., Brady, C.A., Beaudry, V.G., Pathak, N., Han, S., and L. D. Attardi. (2016) p19Arf is required for the cellular response to chronic DNA damage. Oncogene. 35(33): 4414-4421.


Mazur, P.K., Herner, A., Spano Mello, S., Wirth, M., Hausmann, S., Kuschma, T., Sanchez-Rivera, F.J., Lofgren, S., Hahn, S.A., Vangala, D., Trajkovic-Arsic, M., Gupta, A., Heid, I., Noël, P.B., Braren, R., Erkan, M., Kleeff, J., Sipos, B., Sayles, L.C., Heikenwälder, M., Heßmann, E., Ellenrieder, V., Esposito, I., Jacks, T., Bradner, J.E., Khatri, P., Sweet Cordero, E.A., L.D. Attardi, Schmid, R.M., Schneider, G., Sage, J., and Siveke, J.T. (2015) Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Nat Med. 21(10):1163-71.

Younger, S.T., Kenzelmann Broz, D., Jung, H., L. D. Attardi and Rinn, J.L. (2015) Integrative Genomic Analysis Reveals Widespread Enhancer Regulation by p53 in Response to DNA Damage. Nucleic Acids Res.43(9);4447-62.

Van Nostrand, J.L., Brisac, A., Spano Mello, S., Jacobs, S.B.R., Luong, R., and L.D. Attardi. (2015) The p53 Target Gene Siva Enables Non-Small Cell Lung Cancer Development.Cancer Discov.5(6):622-35.

Bieging, K.T., and L.D. Attardi. (2015) Cancer: A Piece of the p53 Puzzle (News & Views). Nature.520(7545):37-8.

Yang, Z.J., Kenzelmann Broz, D., Noderer, W.L., Ferreira, J.P., Overton, K.W., Spencer, S.L., Meyer, T., Tapscott, S.J., L.D. Attardi, and Wang, C.L. (2014) p53 Suppresses Muscle Differentiation at the Myogenin Step in Response to Genotoxic Stress. Cell Death Differ. 22(4):560-73.

Jiang, D., LaGory, E.L., Kenzelmann Brož, D., Bieging, K.T., Brady, C.A., Link, N., Abrams, J.M., Giaccia, A.J., and L. D. Attardi. (2015) Analysis of p53 Transactivation Domain Mutants Reveals Acad11 as a Metabolic Target Important for p53 Pro-Survival Function. Cell Rep. 10(7):1096-109.


Van Nostrand, J.L. and L.D. Attardi. (2014) Guilty as CHARGED: p53’s Expanding Role in Disease. Cell Cycle. 13(24):3798-807.

Van Nostrand, J.L., Brady, C.A., Jung, H., Fuentes, D.R., Kozak, M.M., Johnson, T.M., Lin, C.Y., Lin, C.J., Swiderski, D.L., Vogel, H., Bernstein, J.A., Attié-Bitach, T., Chang, C.P., Wysocka, J., Martin, D.M., and L.D. Attardi. (2014) Inappropriate p53 Activation During Development Induces Features of CHARGE Syndrome. Nature. 514(7521): 228-32.

Li, X., Nadauld, L., Ootani, A., Corney, D.C., Pai, R.K., Gevaert, O., Cantrell, M.A., Rack, P.G., Neal, J.T., Chan, C. W., Yeung, T., Gong, X., Yuan, J., Wilhelmy, J., Robine, S., L.D. Attardi, Plevritis, S.K., Hung, K.E., Chen, C.Z., Ji, H.P., and Kuo, C.J. (2014) Oncogenic Transformation of Diverse Gastrointestinal Tissues in Primary Organoid Culture. Nat Med. 20(7): 769-777.

Bieging, K.T., Spano Mello, S. and L.D. Attardi. (2014) Unravelling Mechanisms of p53-Mediated Tumour Suppression. Nat Rev Cancer. 14(5): 359-70.

Garcia, P.B. and L.D. Attardi. (2014) Illuminating p53 Function in Cancer with Genetically Engineered Mouse Models. Semin Cell Dev Biol. 27: 74-85. 


Kenzelmann Broz, D. and L.D. Attardi. (2013) TRP53 Activates a Global Autophagy Program to Promote Tumor Suppression. Autophagy. 9(9): 1440-42.

Raj, N. and L.D. Attardi. (2013) Tumor Suppression: p53 Alters Immune Surveillance to Restrain Liver Cancer. Curr Biol. 23(12): R527-30.

Spano Mello, S. and L.D. Attardi. (2013) Not All p53 Gain-of-Function Mutants are Created Equal. Cell Death Differ. 20(7): 855-7.

Jiang, D. and L.D. Attardi. (2013) Engaging the p53 Metabolic Brake Drives Senescence. Cell Res. 23(6): 739-40.

Attardi, L.D. and J. Sage. (2013) RB Goes Mitochondrial. Genes Dev. 27(9): 975-9.

Kenzelmann Broz, D., Spano Mello, S., Bieging, K.T., Jiang, D., Dusek, R.L., Brady, C.A., Sidow, A., and L.D. Attardi. (2013) Global Genomic Profiling Reveals an Extensive p53-Regulated Autophagy Program Contributing to Key p53 Responses. Genes Dev. 27(9): 1016-31.

Kong, C.S., Cao, H., Kwok, S., Nguyen, C.M., Jordan, R.C., Beaudry, V.G., L.D. Attardi, and Le, Q.T. (2013) Loss of the p53/p63 Target PERP is an Early Event in Oral Carcinogenesis and Correlates with Higher Rate of Local Relapse. Oral Surg Oral Med Oral Pathol Oral Radiol. 115(1): 95-103. 


Baron, S., Hoang, A., Vogel, H., and L.D. Attardi. (2012) Unimpaired Skin Carcinogenesis in Desmoglein 3 Knockout Mice. PLoSOne 7(11): e50024.

Dusek, R.L., Bascom, J.L., Vogel, H., Baron, S., Borowsky, A.D., Bissell, M.J., and L.D. Attardi. (2012) Deficiency of the p53/p63 Target Perp Alters Mammary Gland Homeostasis and Promotes Cancer. Breast Cancer Res.14(2): R65

Bieging, K.T. and L.D. Attardi. (2012) Deconstructing p53 Transcriptional Networks in Tumor Suppression. Trends Cell Biol.22(2): 97-106. 


Jiang, D., Brady, C.A., Johnson, T.M., Lee, E.Y., Park, E.J., Scott, M.P., and L.D. Attardi. (2011) Full p53 Transcriptional Activation Potential is Dispensable for Tumor Suppression in Diverse Lineages. PNAS 108(41): 17123-8.

Brady, C.A., Jiang, D., Spano Mello, S., Johnson, T.M., Jarvis, L.A., Kozak, M.M., Kenzelmann Broz, D., Basak, S., Park, E.J., McLaughlin, M.E., Karnezis, A.N., and L.D. Attardi. (2011) Distinct p53 Transcriptional Programs Dictate Acute DNA-Damage Responses and Tumor Suppression. Cell 145(4): 571-583.

Dusek, R.L. and L.D. Attardi. (2011) Desmosomes: New Perpetrators in Tumor Suppression. Nat. Rev. Cancer 11(5): 317-23.

Renault, V.M., Thekkat, P.U., Hoang, K.L., White, J.L., Brady, C.A., Kenzelmann Broz, D., Venturelli, O.S., Johnson, T.M., Oskoui, P.R., Xuan, Z., Santo, E.E., Zhang, M.Q., Vogel, H., L.D. Attardi, and Brunet, A. (2011) The Pro-Longevity Gene FoxO3 is a Direct Target of the p53 Tumor Suppressor. Oncogene 30(29): 3207-21.

Jheon, A.H., Mostowfi, P., Snead, M.L., Ihrie, R.A., Sone, E., Pramparo, T., L.D. Attardi, and Klein, O.D. (2011) PERP Regulates Enamel Formation via Effects on Cell-Cell Adhesion and Gene Expression. J. Cell Sci. 124(Pt 5): 745-54. 


Beaudry, V.G., Jiang, D., Dusek, R.L., Park, E.J., Knezevich, S., Ridd, K., Vogel, H., Bastian, B.C., and L.D. Attardi. (2010) Loss of the p53/p63 Regulated Desmosomal Protein Perp Promotes Tumorigenesis. PLoS Genet. 6(10): e1001168.

Huarte, M., Guttman, M., Feldser, D., Garber, M., Koziol, M., Broz, D., Khalil, A.M., Zuk, O., Amit, I., Rabani, M., L.D. Attardi, Regev, A., Lander, E.S., Jacks, T., and Rinn, J.L. (2010) A Large Intergenic Noncoding RNA Induced by p53 Mediates Global Gene Repression in the p53 Response. Cell 142: 409-419.

Brady, C.A. and L.D. Attardi. (2010) p53 at a Glance. J. Cell Sci. 123(15): 2527-2532.

Beaudry, V.G., Ihrie, R.A., Jacobs, S.B.R., Nguyen, B., Pathak, N., Park, E., and L.D. Attardi. (2010) Loss of the Desmosomal Component PERP Impairs Wound Healing In Vivo. Dermatol Res Pract. 2010: 759731.

Kenzelmann Broz, Daniela, and L.D. Attardi. (2010) In vivo analysis of p53 tumor suppressor function using genetically engineered mouse models. Carcinogenesis 31(8): 1311-8. 


Fete, M., Vanbokhoven, H., Clements, S.E., McKeon, F., Roop, D.R., Koster, M.I., Missero, C., Attardi, L.D., Lombillo, V.A., Ratovitski, E., Julapalli, M., Ruths, D., Sybert, V.P., Siegfried, E.C., and A.F. Bree. (2009) International Research Symposium on Ankyloblepharon-Ectodermal Defects-Cleft Lip/Palate (AEC) Syndrome, Am J Med Genet149(9): 1885-93.

Beaudry, V.G., Pathak, N., Koster, M.I., and L.D. Attardi. (2009) Differential Perp Regulation by TP63 Mutants Provides Insight into AEC Pathogenesis, Am J Med Genet. 149(9): 1952-7.

Beaudry, V.G. and L.D. Attardi. (2009) SKP-ing TAp63: stem cell depletion, senescence, and premature aging. Cell Stem Cell 5(1):1-2.

Nguyen, B., Dusek, R.L., Beaudry, V., and L.D. Attardi. (2009) Loss of the Novel Desmosomal protein PERP enhances the phenotypic effects of Pemphigus Vulgaris Autoantibodies. J. Invest. Dermatol. 129(7):1710-8. * Selected for cover image. 


McGowan, K.A., J.Z. Li, C.Y Park, V. Beaudry, H.K. Tabor, A.J. Sabnis, W. Zhang, H. Fuchs, M.H. de Angelis, R.M. Myers, L.D. Attardi and G.S. Barsh. (2008). Mutations in ribosomal proteins cause p53-mediated dark skin and pleiotropic effects. Nat. Genet.40(8):  963-70.

Basak, S., S.B. Jacobs, A.J. Krieg, N. Pathak, Q. Zeng, P. Kaldis, A.J. Giaccia and L.D. Attardi. (2008). The Metastasis-Associated Gene Prl-3 is a p53 Target Involved in Cell-Cycle Regulation. Mol. Cell. 30 (3): 303-314.

Johnson, T.M., K. Meade, N. Pathak, M.R. Marques, and L.D. Attardi. (2008). Knockin Mice Expressing a Chimeric p53 Protein Reveal Mechanistic Differences in How p53 Triggers Apoptosis and Senescence. Proc Natl. Acad. Sci USA105(4): 1215-1220. 


Wijnhoven, S.W.P., E.N. Speksnijder, X. Liu, E. Zwart, C.Th.M. van Oostrom, R.B. Beems, E.M. Hoogervorst, M.M. Schaap, L.D. Attardi, T. Jacks, H. van Steeg, J. Jonkers, and A. de Vries. (2007). Dominant-Negative but not Gain-of-Function Effects of a p53-R270H Mutation in Mouse Epithelium Tissue after DNA Damage. Cancer Res. 67(10):4648-4656.

Jacobs, S.B.R., S. Basak, J.I. Murray, N. Pathak, and L.D. Attardi. (2007). Siva is an Apoptosis-Selective p53 Target Gene Important for Neuronal Cell Death. Cell Death Differ. 14(7):1374-85. 


Ihrie, R.A., R.T. Bronson, and L.D. Attardi (2006). Adult Mice Lacking the p53/p63 Target Gene Perp are not Predisposed to Spontaneous Tumorigenesis but Display Features of Ectodermal Dysplasia Syndromes. Cell Death Differ. 13(9), 1614-1618.

Johnson, T.M. and L.D. Attardi (2006). Dissecting p53 Tumor Suppressor Function in vivo through the Analysis of Genetically Modified Mice. Cell Death Differ. 13(6), 902-908.

Johnson, T.M. and L.D. Attardi (2006). Reply to Explaining the Biological Activity of Transactivation-Deficient p53 Variants. Nat Genet 38, 396-397.

Marques, M.R., R.A. Ihrie, J.S. Horner, and L.D. Attardi (2006). The Requirement for Perp in Postnatal Viability and Epithelial Integrity Reflects an Intrinsic Role in Stratified Epithelia. J. Invest. Dermatol. 126(1), 69-73. 


Attardi, L.D. and L.A. Donehower (2005). Probing p53 Biological Functions Through the Use of Genetically Engineered Mouse Models. Mutat Res.576(1-2), 4-21.

Marques, M.R., J. S. Horner, R.A. Ihrie, R.T. Bronson, and L.D. Attardi (2005). Mice Lacking the p53/p63 Target Gene Perp are Resistant to Papilloma Development. Cancer Res. 65(15), 6551-6556.

Ihrie, R.A. and L.D. Attardi (2005). A New Perp in the Lineup: Linking p63 and Desmosomal Adhesion. Cell Cycle 4(7), 873-876.

Johnson, T.M. and L.D. Attardi (2005). p53QS: An Old Mutant Teaches Us New Tricks. Cell Cycle 4(6), 731-734.

Artandi, S.E. and L.D. Attardi (2005). Pathways Connecting Telomeres and p53 in Senescence, Apoptosis, and Cancer. Biochem Biophys Res Commun. 331(3), 881-890.

Ihrie, R.A., M.R. Marques, B.T. Nguyen, J.S. Horner, C. Papazoglu, R.T. Bronson, A.A. Mills, and L.D. Attardi (2005). Perp is a p63-Regulated Gene Essential for Epithelial Integrity. Cell120(6), 843-856.

Brown, J.M. and L.D. Attardi (2005). The Role of Apoptosis in Cancer Development and Treatment Response. Nat Rev Cancer5(3), 231-237.

Johnson, T.M., E.M. Hammond, A. Giaccia, and L.D. Attardi (2005). The p53QS Transactivation-Deficient Mutant Shows Stress-Specific Apoptotic Activity and Induces Embryonic Lethality. Nat Genet. 37(2), 145-152.

Attardi, L.D. (2005). The Role of p53-Mediated Apoptosis as a Crucial Anti-Tumor Response to Genomic Instability: Lessons from Mouse Models. Mutat Res. 569(1-2), 145-157. 


Ihrie, R.A. and L.D. Attardi (2004). Perp-Etrating p53-Dependent Apoptosis. Cell Cycle. 3(3), 267-269.

Attardi, L.D., A. de Vries, and T. Jacks (2004). Activation of the p53-Dependent G1 Checkpoint Response in Mouse Embryo Fibroblasts Depends on the Specific DNA Damage Inducer. Oncogene. 23(4), 973-980.

Attardi, L.D. and R.A. DePinho (2004). Conquering the Complexity of p53. Nat Genet. 36(1), 7-8. 

Before 2004 (selected publications)

Ihrie, R.A., E. Reczek, J.S. Horner, L. Khachatrian, J. Sage, T. Jacks, and L.D. Attardi (2003). Perp is a Mediator of p53-Dependent Apoptosis in Diverse Cell Types. Curr Biol13(22), 1985-1990.

Attardi, L.D., E.E. Reczek, C. Cosmas, E.G. Demicco, M.E. McCurrach, S.W. Lowe, and T. Jacks (2000). PERP, an Apoptosis-Associated Target of p53, is a Novel Member of the PMP-22/gas3 Family. Genes Dev14(6), 704-718.

Attardi, L.D., S.W. Lowe, J. Brugarolas, and T. Jacks (1996). Transcriptional Activation by p53, but not Induction of the p21 Gene, is Essential for Oncogene-Mediated Apoptosis. EMBO J. 15(14), 3693-3701.

Sah, V.P., L.D. Attardi, G.J. Mulligan, B.O. Williams, R.T. Bronson, and T. Jacks (1995). A Subset of p53-Deficient Embryos Exhibit Exencephaly. Nat Genet. 10(2), 175-180.